Although FGF19 is used to treat metabolic diseases such as nonalcoholic steatohepatitis and diabetes,[35] one study indicated that FGF19 has both lipid‐raising and lipid‐lowering effects that may be mediated by different FGF receptors and target tissues.[36] Our findings reveal that FGF19 activates HSCs in the CRCLM models, which may warrant further investigation into the use of FGF19 analog to treat metabolic diseases in cancer patients. This evidence concerns the gene FGF19 and metabolic dysfunction-associated steatohepatitis.